The venue for this event is The Royal College of Pathologists
2 Carlton House Terrace is the home of the Royal College of Pathologists, a professional membership organisation, concerned with all matters relating to the science and practice of pathology.
Carlton House Terrace was constructed largely between 1826 and 1829 and it remains the property of the Queen.
Its balconies overlook the Mall in central London where Buckingham palace stands.
This is a Euroscicon Small Conference, an outline of the day can be found at
Cell culture has matured to become the pivotal technology in biopharmaceutical research, development and production, and its use in this and other areas continues to expand rapidly. In vitro models are replacing animals in many tests and assays; its enormous potential in the fields of stem cell and regenerative medicine has hardly started to be realized; and its utility in research grows ever faster.
This conference will examine some of the latest applications of cell culture technology, some that are still “over the horizon”, and some of the problems that must be solved before it can reach its full potential.
This event has CPD accreditation
Meeting chair: Dr John Davis, University of Hertfordshire; Vice-Chairman of ESACT-UK
9:00 – 9:45 Registration
9:45 – 10:00 Introduction by the Chair: Dr John Davis, University of Hertfordshire; Vice-Chairman of ESACT-UK
10:00 – 10:30 Assessment of influenza pathogenicity using respiratory ex-vivo organ culture
Bethany Nash, Animal Health and Veterinary Laboratories Agency, Surrey, UK
Pathogenicity studies are historically conducted in whole body systems requiring many animals for statistical significance. We have adapted ex vivo pig organ culture methods to investigate A(H1N1)pdm09 and Eurasian lineage H5N1 influenza virus pathogenesis in both pig and ferret systems as models of host and human influenza infection. This has enabled the number of animals used to be substantially reduced. Using real-time RT-PCR and immunohistochemistry we have investigated viral infection in both upper and lower respiratory tract infections to inform influenza pandemic preparedness.
10:30 – 11:00 Cell Performance Monitoring On-Line
Philip Matthius, Applikon Biotechnology UK
An innovative implementation of a new Quantitative microscopic imaging platform is used as a tool for on-line monitoring of viable cell density in bioreactors. This label-free technology can be used throughout the bioreactor cycle and will allow the user to track cell quantities, viability and morphology in real-time eliminating the need for sampling and reducing the risk of contamination. Tracking cell growth continuously allows for accurate prediction of optimum harvest times.
11:00 – 11:30 Speakers’ photo then mid-morning break/networking and trade show
Please try to visit all the exhibition stands during your day at this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
11:30 – 12:00 Alternative cell sources for ocular surface stem cell therapy
Dr Anna O'Callaghan, UCL Institute of Ophthalmology, UK
Limbal epithelial stem cells are responsible for the maintenance and repair of the corneal surface. Injury and disease can result in a deficiency of these stem cells affecting vision in these patients. Cultured limbal epithelial stem cell therapy can be used to repair the corneal surface. It is not always possible to use the patient's own corneal cells for this, and the use of alternative sources of stem cells from the patient such as from the mouth (oral mucosa) will be discussed.
12:00 – 12:30 Investigating murine pluripotency using distinct culture conditions
Dr Kirsten McEwen, MRC Clinical Sciences Centre, Hammersmith Hospital, UK
Murine embryonic stem cells provide a useful system to delineate the processes underlying naïve pluripotency. We have compared the transcriptional and epigenetic profiles of pluripotent cells cultured under two different culture conditions: traditional serum-containing and dual inhibition of Erk and Gsk3b, termed 2i. Distinct epigenetic properties are apparent, including altered abundance of DNA methylation. Our findings establish that culture in 2i instils a naïve pluripotent state with a distinctive epigenetic configuration that parallels several molecular features observed in the original in vivo cell population.
12:30 – 13:30 Lunch/networking and trade show
This is also a good time to fill out your feedback forms and any questionnaires
13:30 – 14:00 Question and Answer Session
Delegates will be asked to submit questions to a panel of experts. Questions can be submitted before the event or on the day
14:00-14:30 Online Monitoring and Control of Glucose and Lactate in Small Volume Bioreactors
Soenke Rosemann, Sartorius Stedim Biotech GmbH, Göttingen, D-37079, Germany
BioPAT®Trace is a dual-channel analyzer for the measurement of glucose and lactate. The online analyzing system BioPAT®Trace covers demands of long-term cell cultures and fast microbial processes in different scales such as small volume cultivations and large scale productions. The sterile sampling systems, based on filtration or dialysis, probes provide the perfect solution for reliable online sampling in bioreactors used in industrial and laboratory facilities. Special attention has been paid to ease of use in small scale cultivations. The dialysis mode of the BioPAT®Trace allows to collect data on glucose and lactate concentrations automatically and frequently without reducing the culture volume.
14:30 - 15:00 Strategies for Increasing Protein Expression in Mammalian Transient Transfection Systems
Dr. Jonathan Zmuda, Life Technologies, USA
Recent advances have allowed transient protein expression to become a fast, flexible and economical way to produce high quality recombinant proteins without the time and cost associated with generating stably transfected cell lines. The levels of protein generated via transient expression, however, have tended to be significantly lower than those of stably transfected cell lines, and when large amounts of protein are required, stable cell lines are often still preferred to transient systems. In order to further increase the utility of transient protein expression, the next key advances will need to approach, or equal, expression levels attained using stable expression systems without losing the speed and flexibility of transient systems. Here, we report on the development of a novel transient transfection system that uses high density HEK293F cell cultures to generate expression levels of greater than 1 g/L and the strategies utilized to achieve these results.
15:00 – 15:30 Afternoon Tea/Coffee, networking and trade show
15:30 – 16:00 Recent advances in production of challenging proteins, using a proprietary Drosophila S2 cell-based platform: robustness, scalability, cGMP production
Dr Wian de Jongh, CSO of Expres2ion Biotechnologies, Denmark
Drosophila S2 cells represent a efficient cGMP compatible eukaryotic platform for recombinant protein expression. Expres2ion has developed a proprietary and complete licensable production platform, to serve unmet needs in vaccine and research applications. The platform and relevant applications will be described.
16:00 – 16:30 Industrially Generated Red Blood Cells for Transfusion
Dr Nik Willoughby, Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University
Blood Transfusion has become a mainstay of modern medical practice. However problems persist both nationally and internationally in maintaining supply, managing the risk of transmission of infectious agents and ensuring immune compatibility between donor and recipient. Human embryonic stem cells (hES cells) offer a potentially limitless source from which to generate red blood cells (RBCs) for use in clinical transfusion. The work presented here will describe some of the biological and engineering challenges associated with scale-up of the cell culture and purification operations used to produce the large numbers of RBCs necessary for potential clinical supply.
Although this presentation describes development of a specific process, it is likely that the greatest scale-up hurdles will be specific to cellular therapies as a whole; therefore it is timely to consider process development now in order to prevent a major bottleneck occurring when allogeneic cellular therapies reach clinical trials.
16:30 – 17:00 Next generation assays based on mechanistic toxicity for cell health monitoring
Mr Craig Malcolm, Promega UK, UK
Investigating cytotoxicity in vitro often begins with measuring the number of viable cells remaining in cultures incubated with test compounds for 1-3 days. Alternatively, the number of dead cells can be measured by detecting biomarkers that leak from damaged cells into the culture medium. Currently available assay technologies will be described which go beyond providing simple “live or dead” information to indicate whether cells have died by apoptosis or necrosis. New methods which can detect involvement of various organelles and cellular pathways that may trigger events leading to cell death will also be discussed. The knowledge of which pathways are involved provides important information that can lead to identification of the molecular targets involved with initiating cytotoxic events. This talk will present an overview of methods for directly measuring cytotoxicity, detecting upstream pathways indirectly leading to cytotoxicity, and multiplexing assay combinations to more efficiently determine events leading to cell death. The growing importance of 3D cultures will also be discussed with data to describe developments in relation to optimised reagents for determining cell health status in the 3D culture paradigm.
17:00 Chairman’s summing up
About the Chair
John Davis is Visiting Lecturer in Biotechnology at the University of Hertfordshire, and Chairman of the UK Branch of the European Society for Animal Cell Technology (ESACT-UK). After a degree in Biochemistry at Sheffield, he moved in 1974 to Renato Dulbecco’s laboratory where he was initiated into the art of cell culture. Following PhD studies in Leicester, he moved to Switzerland, working with both Norman Iscove and Georges Köhler, the latter starting him on his many years of research into the use of monoclonal antibodies, particularly in therapy. After a further postdoctoral position, at the University of Cambridge where he worked on the early stages of the development of Campath (Alemtuzumab; now also known as Lemtrada), he made the transition to industry, working first for PA Technology and then (for nearly 20 years) for the Bio-Products Laboratory. In 2007 he made the transition back to academia. In addition to undergraduate and postgraduate teaching, he now runs open courses on Basic Cell Culture and Intermediate/Advanced Cell Culture. He has served on both the UKCCCR subcommittee on the Use of Cell Lines in Cancer Research, and the EC task force on Good Cell Culture Practice. In addition he has edited a number of books on cell culture, including Basic Cell Culture: A Practical Approach, and (with Glyn Stacey) Medicines from Animal Cell Culture. His most recent book is Animal Cell Culture: Essential Methods, which was published in March 2011 by Wiley-Blackwell
About the speakers
After graduating from University College London in 1996 with a BEng in Biochemical Engineering, Nik Willoughby carried out a PhD within the Advanced Centre for Biochemical Engineering at UCL. Entitled "An Engineering Evaluation of Expanded Bed Adsorption for the Recovery of a Typical Bioproduct", the study looked at hydrodynamic and kinetic influences on the performance of this novel unit operation. After completing his PhD he worked for two years in purification development at Metris Therapeutics, before returning to UCL to help establish the Innovative Manufacturing Research Centre for Bioprocessing. This multi-disciplinary research group was funded by the EPSRC to facilitate rapid development and scale-up of bioprocesses. Nik moved to Heriot-Watt in April 2006, as part of the ScotChem initiative. His research group at Heriot-Watt is currently focused on scalable culture, purification and separation of stem cell-based cellular therapies. Under the BBSRC BRIC initiative they are investigating scalable separation of human adult and embryonic stem cells and have just started a major SFC-funded project looking at developing a manufactured hESC-derived replacement for donated blood. In addition Nik is heavily involved in sustainability strategies to reduce CO2 emissions from chemical and biological plant using novel techniques based around cyanobacterial photosynthetic fixation. In connection with this he is about to commence a Horizon-funded project developing techniques to produce added-value protein and bioenergy products within the brewing and distilling industry.
Craig Malcolm, PhD is currently Product Manager for Cell Analysis and Proteomics at Promega UK, based in Southampton. After receiving his PhD in Neurochemistry from St Andrews University he was in the pharmaceutical industry for seven years as a Team Leader in Molecular Pharmacology (Vernalis Ltd.), developing cell-based assays and supporting drug discovery screening projects. After several more years in product development as a Senior Cell Biologist (PerkinElmer), and various other roles in several other UK-based Life Sciences companies (Scientifica, Roche Applied Science), Dr Malcolm joined Promega UK last year and is responsible for cell-based assay reagents, proteomics products and related instrumentation in these areas.
Anna O'Callaghan is part of the Cells for Sight group headed by Professor Julie Daniels at the University College London Institute of Ophthalmology. Anna has been a Post-Doc there since 2009. Anna obtained her undergraduate degree in Biochemistry at the University of East Anglia, a Masters degree in Biochemical Engineering at University College London, and an Engineering Doctorate at University College London on limbal epithelial stem cells.
Bethany Nash has been a Senior Research Assistant within the Mammalian and Avian Influenza group at the Animal Health and Veterinary Laboratories Agency (AHVLA), Weybridge for 3 and a half years. Currently her work centres around inter-species transmission dynamics of influenza [e.g. H5N1 and A(H1N1)pdm09] and studying emerging influenza threats for pandemic preparedness planning. Previous to the AHVLA, Bethany spent time at the Centre of Infectious Diseases, Health Protection Agency, London researching correlates of immune response in human papillomavirus and cervical cancer.
Willem Adriaan (Wian) de Jongh, PhD, CSO and co-founder, ExpreS2ion Biotechnologies
Dr. de Jongh (South African) obtained a Bachelor degree followed by a M.Sc. (cum laude) in Chemical Engineering from the University of Stellenbosch, South Africa. Thereafter, he was awarded a doctorate in Biotechnology from DTU in 2006. During his PhD, Dr. de Jongh developed advanced cell line genetic engineering tools and applied metabolic engineering methodologies to cell lines with engineered improved production characteristics. Dr. de Jongh has six years’ experience in the pharmaceutical industry in molecular biology; cell line development; project management; upstream process development; process scale-up; and process transfer to cGMP manufacturing. Furthermore, Dr. de Jongh was instrumental in the development of the proprietary expression vector system ExpreS2ion Biotechnologies was founded on. Dr. de Jongh has also served on the steering committee and as project manager on several grant funded projects.
Nik Willoughby obtained his degree and PhD from UCL before spending time in industry with Metris Therapeutics and Lonza Biologics. In 2002, Nik returned to UCL to help establish the Innovative Manufacturing Research Centre for Bioprocessing. Nik moved to Heriot-Watt in 2006 to establish a cellular bioprocessing research group, with the group's focus divided between cellular therapies and sustainability research. Currently the cellular therapies team are focused on scalable culture, purification and separation of stem cell-based cellular therapies.
Kirsten McEwen completed a Biomedical Science Honours degree in New Zealand before undertaking a PhD in genomic imprinting at the University of Cambridge, UK with Anne Ferguson-Smith. Kirsten has continued her academic career as a post-doctoral fellow at the MRC Clinical Sciences Centre in London, working under Petra Hajkova in the Reprogramming and Chromatin group. Kirsten's focus is on basic reseach of epigenetic mechanisms in murine pluripotent stem cells.
Guy Matthews has worked at SAFC as a Technical Manager for the past 18 months, supporting Customers and SAFC’s Business Development teams in biomanufacturing, this has been mostly focused on the development of upstream processes. Prior to joining SAFC Guy worked at Millipore in a business development role focused around the use of single use technology in bioproduction in both upstream and downstream. Prior to this Guy worked at a CMO in a quality function and has held a number of Business Development roles. The common factor in his career to date has been all the roles have been in the Biotechnology arena
Jonathan Zmuda, Ph.D., is an Associate Director of R&D leading the Cell Culture Essentials group at Life Technologies. Dr. Zmuda received his Ph.D. in Cell Biology from the University of Maryland, College Park, USA. Prominent among his roles, Dr. Zmuda works to discover, develop and commercialize technologies and products useful for cell biology applications, including cell-based assays, protein expression, cell culture media development, rare cell analysis and instrumentation while also focusing on the development, qualification and validation of methods used for QC testing.
Soenke Rosemann has a degree in business administration and in life sciences. Before starting to work for Sartorius Stedim Biotech he was with a venture capital company, focused on financing early stage companies in life sciences. Currently he is working in the Sartorius product management team for process analytical technology.
Philip Mathuis is founder and CEO of Ovizio Imaging Systems, a spin-off of the Université Libre de Bruxelles (ULB). After receiving his engineering degree he started his career in the telecommunications sector where he held management positions in several European countries. He obtained an MBA from ESCP Europe in Paris and is a seasoned entrepreneur with a passion for science and technology.
Keywords: cell, transfection, lasers, microscopy, Autophagy, Puncta, p62, Flux, cell, transfection, lasers, microscopy, dry powder, mammalian cell culture media, batch to batch consistency, human embryonic stem cells, clinical grade, cGMP, bioreactor, process development, large scale, upstream processes, recombinant protein production; cold-shock; CHO cells; cell engineering, cornea, eye, limbal epithelial stem cells, cell therapy,Influenza, organ culture, pigs, ferrets, respiratory tract,Soluble proteins, vaccines, cGMP,Drosophila , Red blood cells, human embryonic stem cells, scale-up, DNA methylation, genomic imprinting, pluripotency, Cell Line Selection, Media Development, cell, apoptosis, multiplexing, pathways, 3D culture, Online Monitoring,Glucose, Lactate
Event Web site: www.regonline.co.uk/cellculture2013
FOR POSTER PRESENTATION
EFFECT OF DOXORRUBICIN IN CELL CULTURE OF CANINE BREAST TUMORS AND ITS CORRELATION WITH TGF-β1 EXPRESSION
S.S. SAKAMOTO, D. STOCKMANN, H.F. FERRARI, T.C. CARDOSO, A.L. ANDRADE
São Paulo State University, UNESP, Veterinary School, Laboratory of Virology, Clovis Pestana Street - 793, Araçatuba, 16.050-680, Brazil. Corresponding author: email@example.com
3D CULTURE PADRONIZATION OF BITCHES MAMMARY TUMOUS
S.S. SAKAMOTO, D. STOCKMANN, T.C. CARDOSO, A.L. ANDRADE
CORRELATION OF TRACE ELEMENTS IRON, COOPER AND ZINC OF CANINE MAMMARY TUMOR SAMPLES AND TOTAL NUMBER OF CELLS FROM ITS CELL CULTURE
AL ANDRADE, SS SAKAMOTO, DS SILVA, TC CARDOSO, SCAPIN MA
São Paulo State University,UNESP, Veterinary School, Laboratory of Virology, Clovis Pestana Street, Araçatuba, 16.050-680, Brazil. Correspondig author: firstname.lastname@example.org
GRAM PER LITER EXPRESSION OF BIOLOGICALLY-ACTIVE AND PROPERLY GLYCOSYLATED PROTEINS USING A NOVEL MAMMALIAN TRANSIENT TRANSFECTION SYSTEM
CY LIU , MB JONES, S VASU, I CISNEROS, D BEZDEK, J ROGERS, H CHIOU, J ZMUDA
Life Technologies, 7335 Executive Way, Frederick MD, USA
DEVELOPMENT OF CELL CULTURE BASED LIVE VACCINE OF AAV-4 AND COMPARATIVE EVALUATION OF ITS EFFICACY WITH COMMERCIAL VACCINE
1,2ASMA JABEEN, 2KHALID NAEEM, 2TAHIRA KAMAL, 1S.M SAQLAIN NAQVI
1- Department of biochemistry PMAS ARID Agriculture university Rawalpindi Pakistan
2- National Reference Labortary for poultry Diseases, Animal Sciences Institute, National Agricultural Research Centre Islamabad, Pakistan.
Email corresponding author and presenting author email@example.com
Phone: 07507 799380
For all accommodation and travel enquiries please contact firstname.lastname@example.org
For enquiries regarding payment email: email@example.com
You can pay by - Credit card, Cheque, Purchase Order or Bank transfer.
Payment must be received prior to the meeting
You can pay during your online registration using your credit card. The information taken will be by secure server and we use Worldpay and PayPal for our credit card transactions. We always prefer debit cards for transactions, but can also take credit cards and American Express. Using this mode of payment you can guarantee that your fee has reached us prior to the conference and you will be listed as registered
Cheques should be made payable to Euroscicon and mailed (together with a print out of the invoice which will be available at the end of the registration process). After registration you will be emailed details of where to send your cheque.
Please input your Purchase Order number in the box provided once you have selected your mode of payment and an invoice will be sent to you accordingly
Clients organizing bank transfers from non-UK banks will need to pay an additional administration fee of £15.00. Please ensure that you add this fee onto your payment to ensure successful registration. After registration you will be emailed details of where transfer your money.
An event from European Scientific Conferences - Euroscicon "Specialising in communicating cutting edge technology & methodology in the Life Sciences"
EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Registered Office: 47 Falkland Road, High Barnet, EN5 4LQ.